O'Shea L , Fair T , Hensey C .

	Figure 1. AVEN expression and subcellular localization in oocytes. (a) Representative western blot analysis of Aven expression in stage II–stage VI oocyte extracts. GAPDH was used as a loading control (n=5). (b) Western blot analysis of stage VI whole oocyte extract, cytoplasmic extract and nuclear extract (n=3). (c) Aven expression in embryos from single cell to stage 11.5 (n=3). (d) Aven morpholino results in a loss of Aven expression at GVBD (n=6). (e) Phosphatase treatment of Stage II and Stage VI oocytes caused depletion of the 46-kDa Aven band, (n=3)
	Figure 2. Dynamic changes in Aven expression during oocyte maturation. (a) Western blot analysis of Aven in oocyte extracts before and at the indicated time points (hours) after progesterone (P4) addition. In all, 64% of oocytes reached GVBD by 3.5  h as determined by the appearance of a white spot (92% at 4 h) and GVBD and MII were confirmed by pMAPK and pHistone-H3 expression. Aven expression is rapidly lost on progesterone addition and recovers by GVBD, error bars correspond to S.D. based on four experiments. (b) Loss of Aven expression following calcium ionophore A23187 induced metaphase release, error bars correspond to S.D., (n=4). (c) Fluctuations in Aven expression in cycling extracts with pHistone-H3 peaks marking the M phase of the cell cycle
	Figure 3. AVEN protein depletion in oocytes increases progesterone sensitivity, facilitates rapid GVBD but ultimately results in oocyte death. (a) % GVBD in uninjected, control morpholino (MO)-injected and Aven morpholino (MO)-injected progesterone-treated oocytes (80–120 oocytes per experiment). Shown is a representative experiment from n=5. (b) Columns represent the average time taken for 50% GVBD to occur; error bars correspond to S.D., (n=5). (c) Western blot analysis of pMAPK expression in uninjected and AVEN MO-injected oocytes at the indicated times after progesterone addition. pMAPK is evident 1 h earlier in Aven MO-treated oocytes. (d) Oocyte survival was scored at the indicated times in uninjected, control MO and AVEN MO-injected oocytes. Aven MO-treated embryos gradually die as determined by gross morpholoigcal features. (e) Columns represent % GVBD in uninjected and Aven MO-injected oocytes 5 h after addition of the indicated progesterone concentrations. Loss of Aven increases the sensitivity of oocytes to progesterone. Error bars correspond to S.D., (n=5). (f) The apoptotic morphology of Aven-depleted oocytes as compared with control oocytes represented in d. Columns with different letters indicate significant differences (P<0.05)
	Figure 4. Cell death activation in Aven-depleted oocytes. (a) Western blot analysis for active caspase-3 expression in uninjected, control MO-injected and Aven MO-injected, progesterone-treated oocytes (100–120 oocytes per experiment). Active caspase-3 was only detected in Aven-depleted oocytes 5 h after progesterone treatment. Shown is a representative experiment from n=7. (b) Representitive images (light and fluorescence) of Aven MO-injected oocytes undergoing precocious GVBD and subsequent apoptosis at the indicated times after progesterone addition. (c) A comparison of Aven–Bcl-xL interaction in control and apoptotic oocytes. Aven and Bcl-xL immunoprecipates were analyzed by western blot at GV, GVBD, MII and MII*: an MII equivalent time point in irradiated oocytes (n=3). Normal rabbit IgG antibody was used in control immunoprecipitations. Bcl-xL is bound to Aven in immoprecipiated MII-arrested egg extract, whereas in DNA damage-induced apoptotic extracts, little Aven is assoictaed with Bcl-xL

Buys, Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. 2007, Pubmed

Buys, Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. 2007, Pubmed
Chau, Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. 2000, Pubmed
Daar, Inhibition of mos-induced oocyte maturation by protein kinase A. 1993, Pubmed , Xenbase
Dorai, Combining high-throughput screening of caspase activity with anti-apoptosis genes for development of robust CHO production cell lines. 2010, Pubmed
Dumont, Oogenesis in Xenopus laevis (Daudin). I. Stages of oocyte development in laboratory maintained animals. 1972, Pubmed , Xenbase
Esmaili, Regulation of the ATM-activator protein Aven by CRM1-dependent nuclear export. 2010, Pubmed , Xenbase
Evans, Biochemical fractionation of oocytes. 1991, Pubmed , Xenbase
Figueroa, Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions. 2004, Pubmed
Finidori-Lepicard, Progesterone inhibits membrane-bound adenylate cyclase in Xenopus laevis oocytes. 1981, Pubmed , Xenbase
Guo, Aven-dependent activation of ATM following DNA damage. 2008, Pubmed , Xenbase
Heasman, Fertilization of cultured Xenopus oocytes and use in studies of maternally inherited molecules. 1991, Pubmed , Xenbase
Ina, Expression of the mouse Aven gene during spermatogenesis, analyzed by subtraction screening using Mvh-knockout mice. 2003, Pubmed
Kutuk, Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. 2010, Pubmed
Lange-zu Dohna, A CDE/CHR tandem element regulates cell cycle-dependent repression of cyclin B2 transcription. 2000, Pubmed
Laurentino, Apoptosis-inhibitor Aven is downregulated in defective spermatogenesis and a novel estrogen target gene in mammalian testis. 2011, Pubmed
Liu, The anaphase-promoting complex/cyclosome inhibitor Emi2 is essential for meiotic but not mitotic cell cycles. 2006, Pubmed , Xenbase
Maller, Progesterone-stimulated meiotic cell division in Xenopus oocytes. Induction by regulatory subunit and inhibition by catalytic subunit of adenosine 3':5'-monophosphate-dependent protein kinase. 1977, Pubmed , Xenbase
Matten, Protein kinase A acts at multiple points to inhibit Xenopus oocyte maturation. 1994, Pubmed , Xenbase
Melzer, The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential. 2012, Pubmed
Murray, Cell cycle extracts. 1991, Pubmed
Nilsson, Interactions between progesterone and tumor necrosis factor-alpha in the regulation of primordial follicle assembly. 2006, Pubmed
Nutt, Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. 2005, Pubmed , Xenbase
Paydas, Survivin and aven: two distinct antiapoptotic signals in acute leukemias. 2003, Pubmed
Sadler, Progesterone inhibits adenylate cyclase in Xenopus oocytes. Action on the guanine nucleotide regulatory protein. 1981, Pubmed , Xenbase
Sauerwald, Combining caspase and mitochondrial dysfunction inhibitors of apoptosis to limit cell death in mammalian cell cultures. 2006, Pubmed
Selga, Networking of differentially expressed genes in human cancer cells resistant to methotrexate. 2009, Pubmed
Shibuya, G2 cell cycle arrest--a direct link between PKA and Cdc25C. 2003, Pubmed
Smith, Oogenesis and oocyte isolation. 1991, Pubmed , Xenbase
Smith, The induction of oocyte maturation: transmembrane signaling events and regulation of the cell cycle. 1989, Pubmed
Turowec, Regulation of caspase pathways by protein kinase CK2: identification of proteins with overlapping CK2 and caspase consensus motifs. 2011, Pubmed
Walker, Unmasking mRNA in clam oocytes: role of phosphorylation of a 3' UTR masking element-binding protein at fertilization. 1996, Pubmed
Zou, Identification of dAven, a Drosophila melanogaster ortholog of the cell cycle regulator Aven. 2011, Pubmed , Xenbase
Zou, An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. 1999, Pubmed